Makers Laboratories shareholders have approved the appointment of Saahil Parikh as a Non-Executive, Non-Independent Director of the company. The resolution was passed through a postal ballot process concluded on October 19, 2026.

The voting results indicate overwhelming support for the proposal. Out of the total votes polled, 99.99% were cast in favour of the appointment. Only 276 votes were recorded against the resolution, representing a negligible fraction of the total participation.

Voting breakdown by shareholder category

The postal ballot saw participation primarily from the promoter group and public shareholders. The promoter and promoter group voted unanimously in favour, while public institutional holders did not participate in the voting process.

What the numbers show

The data reveals a distinct pattern in shareholder engagement across different categories. While the promoter group exercised 100% of their holding rights, public institutional holders recorded zero votes despite holding 22,897 shares. In contrast, public individual shareholders (Public Others) participated at a rate of 7.76%, casting 175,468 votes out of their 2,262,123 shares held. This suggests that retail investors were significantly more engaged in this specific governance matter than institutional investors, who remained passive on this resolution.

Makers Laboratories has initiated a postal ballot process to seek shareholder approval for the appointment of Mr. Saahil Parikh as a Non-Executive, Non-Independent Director. The appointment, effective from August 11, 2026, marks a transition in leadership structure following Mr. Parikh’s tenure as the company’s Whole-time Director and Chief Executive Officer.

The Board of Directors, acting on the recommendation of the Nomination and Remuneration Committee, proposed the resolution after Mr. Parikh decided not to continue in his executive role due to personal and professional reasons. He will now serve as a non-executive director liable to retire by rotation.

Voting Process and Timeline

The postal ballot notice was dispatched electronically on September 15, 2026, to shareholders registered as of the cut-off date, September 11, 2026. In compliance with Ministry of Corporate Affairs circulars, physical copies are not being sent; voting is restricted to remote e-voting via the National Securities Depository Limited platform.

The e-voting window opens at 9:00 am on September 17, 2026, and concludes at 5:00 pm on October 16, 2026. The results will be declared within two working days of the voting conclusion. Ms. Jigyasa N. Ved of M/s. Parikh & Associates has been appointed as the scrutinizer for the process.

Director Profile and Tenure

Mr. Saahil Parikh brings approximately 25 years of experience in pharmaceutical production, quality control, projects, and general management. He holds a B.Sc. in Bio-Chemistry from Gujarat University and a Diploma in Management Studies from Ahmedabad Management Association.

He served as the Whole-time Director/CEO from August 11, 2011, until August 10, 2026. During the financial year 2025-26, he attended all five board meetings held by the company. His last drawn remuneration as Whole-time Director was ₹73.34 lakh. As a Non-Executive Director, he will receive sitting fees for attending board and committee meetings.

What the Numbers Show

The transition reflects a structural shift in compensation and governance rather than an operational change in leadership continuity. While Mr. Parikh’s previous remuneration was fixed at ₹73.34 lakh annually as an executive, his new role involves variable sitting fees, aligning his compensation with attendance rather than fixed executive duties. He retains a shareholding of 21,741 equity shares, maintaining a financial stake in the company despite stepping down from day-to-day management.